Ireland· IE-PA-EU/1/23/1756/001
Inaqovi 35 mg/100 mg film-coated tablets
A decitabin, kombinationen product containing decitabine + cedazuridine, registered in Ireland by Otsuka Pharmaceutical Netherlands B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Decitabin, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC L01BC58 (decitabin, kombinationen), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 6 of them publish a price we can compare per daily dose
Decitabin, kombinationen · ATC L01BC58
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
HPRA (Ireland)- Active substance
- Decitabine + Cedazuridine
- Manufacturer
- Otsuka Pharmaceutical Netherlands B.V.
- Country
- Ireland (IE)
- ATC code
- L01BC58
- ATC class
- Decitabin, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1756/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Decitabin, kombinationen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaINQOVITAIHO PHARMA CANADA, INC.
- CzechiaINAQOVIOtsuka Pharmaceutical Netherlands B.V., Amsterdam
- SpainINAQOVI 35 MG/100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAOtsuka Pharmaceutical Netherlands B.V.
- FinlandInaqoviOtsuka Pharmaceutical Netherlands B.V.
- United KingdomInaqovi 35mg/100mg tabletsOtsuka Pharmaceuticals (U.K.) Ltd
- IcelandInaqoviOtsuka Pharmaceutical Netherlands B.V.*
- NetherlandsInaqovi 35 mg/100, fimomhulde tablettenOtsuka Pharmaceutical Netherlands B.V.
- NorwayInaqoviOtsuka Pharmaceutical Netherlands B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inaqovi
- Liechtenstein · Inaqovi
- Norway · Inaqovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b5965f1c-bf44-4a98-aa3a-bbb280112e6c GET /v1/drugs/b5965f1c-bf44-4a98-aa3a-bbb280112e6c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01BC58"
],
"strength": null,
"pa_number": "EU/1/23/1756/001",
"substances": [
"Decitabine",
"Cedazuridine"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "15/09/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about decitabin, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.